Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone

Arthritis and Rheumatism

Volumn 63, Issue 8, 2011, Pages 2385-2395

  Marenzana, M ^a,b   Greenslade, K ^a   Eddleston, A ^a   Okoye, R ^a   Marshall, D ^a   Moore, A ^a   Robinson, M K ^a  

^a UCB PHARMA   (Belgium)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ACID PHOSPHATASE TARTRATE RESISTANT PHOSPHATASE 5B; AMINO TERMINAL TELOPEPTIDE; DEXAMETHASONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY SCL ABI; OSTEOCALCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE GROWTH; BONE STRENGTH; BONE TURNOVER; CONTROLLED STUDY; CORTICAL BONE; DIAPHYSIS; DRUG EFFECT; FEMUR; GROWTH RETARDATION; METAPHYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRABECULAR BONE;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE DENSITY; DEXAMETHASONE; FEMUR; GLUCOCORTICOIDS; GLYCOPROTEINS; GROWTH; MICE; OSTEOGENESIS;

EID: 79961118892     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30385     Document Type: Article

References (39)

1. Curtis JR, Westfall AO, Allison J, Bijlsma JW, Freeman A, George V, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 2006; 55: 420-6. (Pubitemid 43887028)
2. Canalis E, Mazziotti G, Giustina A, Bilezikian JP,. Glucocorticoid- induced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007; 18: 1319-28. (Pubitemid 47389469)
3. Patschan D, Loddenkemper K, Buttgereit F,. Molecular mechanisms of glucocorticoid-induced osteoporosis. Bone 2001; 29: 498-505. (Pubitemid 33124290)
4. Lane NE, Yao W, Balooch M, Nalla RK, Balooch G, Habelitz S, et al. Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunas size that are not observed in placebo-treated or estrogen-deficient mice. J Bone Miner Res 2006; 21: 466-76.
5. Avioli LV,. Glucocorticoid effects on statural growth. Br J Rheumatol 1993; 32 Suppl 2: 27-30. (Pubitemid 23179592)
6. Allen DB,. Growth suppression by glucocorticoid therapy. Endocrinol Metab Clin North Am 1996; 25: 699-717. (Pubitemid 26304481)
7. Atman A, Hochberg Z, Silbermann M,. Interactions between growth hormone and dexamethasone in skeletal growth and bone structure of the young mouse. Calcif Tissue Int 1992; 51: 298-304.
8. Van der Eerden BC, Karperien M, Wit JM,. Systemic and local regulation of the growth plate. Endocr Rev 2003; 24: 782-801. (Pubitemid 38067699)
9. Silvestrini G, Ballanti P, Patacchioli FR, Mocetti P, Di Grezia R, Wedard BM, et al. Evaluation of apoptosis and the glucocorticoid receptor in the cartilage growth plate and metaphyseal bone cells of rats after high-dose treatment with corticosterone. Bone 2000; 26: 33-42.
10. Chrysis D, Ritzen EM, Savendahl L,. Growth retardation induced by dexamethasone is associated with increased apoptosis of the growth plate chondrocytes. J Endocrinol 2003; 176: 331-7. (Pubitemid 36410417)
11. Smink JJ, Gresnigt MG, Hamers N, Koedam JA, Berger R, Van Buul-Offers SC,. Short-term glucocorticoid treatment of prepubertal mice decreases growth and IGF-I expression in the growth plate. J Endocrinol 2003; 177: 381-8. (Pubitemid 36722293)
12. Koedam JA, Smink JJ, van Buul-Offers SC,. Glucocorticoids inhibit vascular endothelial growth factor expression in growth plate chondrocytes. Mol Cell Endocrinol 2002; 29; 197: 35-44. (Pubitemid 35304775)
13. Paszty C, Turner CH, Robinson MK,. Sclerostin: a gem from the genome leads to bone-building antibodies. J Bone Miner Res 2010; 25: 1897-904.
14. Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 2001; 68: 577-89. (Pubitemid 32202753)
15. Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001; 10: 537-43. (Pubitemid 32184286)
16. Beighton P,. Sclerosteosis. J Med Genet 1988; 25: 200-3.
17. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 2003; 22: 6267-76. (Pubitemid 37522584)
18. Van Bezooijen RL, Svensson JP, Eefting D, Visser A, van der Horst G, Karperien M, et al. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res 2007; 22: 19-28. (Pubitemid 46032593)
19. Eddleston A, Marenzana M, Moore AR, Stephens P, Muzylak M, Marshall D, et al. A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis. J Bone Miner Res 2009; 24: 1662-71.
20. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009; 24: 578-88.
21. Ominsky M, Vlasseros F, Jolette J, Smith S, Stouch B, Doellgast G, et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 2010; 25: 948-59.
22. Agholme F, Li X, Isaksson H, Ke HZ, Aspenberg P,. Sclerostin antibody treatment enhances metaphyseal bone healing in rats. J Bone Miner Res 2010; 25: 2412-8.
23. Padhi D, Jang G, Stouch B, Fang L, Posvar E,. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011; 26: 19-26.
24. Chen M, Zhu M, Awad H, Li TF, Sheu TJ, Boyce BF, et al. Inhibition of β-catenin signaling causes defects in postnatal cartilage development. J Cell Sci 2008; 1; 121: 1455-65. (Pubitemid 351936310)
25. Van Bezooijen RL, Bronckers AL, Gortzak RA, Hogendoorn PC, van der Wee-Pals L, Balemans W, et al. Sclerostin in mineralized matrices and van Buchem disease. J Dent Res 2009; 88: 569-74.
26. Turner CH, Burr DB,. Basic biomechanical measurements of bone: a tutorial. Bone 1993; 14: 595-606.
27. Krishnan V, Bryant HU, MacDougald OA,. Regulation of bone mass by Wnt signaling. J Clin Invest 2006; 116: 1202-9.
28. Yao W, Cheng Z, Pham A, Busse C, Zimmermann EA, Ritchie RO, et al. Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization. Arthritis Rheum 2008; 58: 3485-97.
29. Hayashi K, Yamaguchi T, Yano S, Kanazawa I, Yamauchi M, Yamamoto M, et al. BMP/Wnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: potential therapeutic targets for glucocorticoid-induced osteoporosis. Biochem Biophys Res Commun 2009; 379: 261-6.
30. Wang FS, Lin CL, Chen YJ, Wang CJ, Yang KD, Huang YT, et al. Secreted frizzled-related protein 1 modulates glucocorticoid attenuation of osteogenic activities and bone mass. Endocrinology 2005; 146: 2415-23. (Pubitemid 40577529)
31. Wang FS, Ko JY, Yeh DW, Ke HC, Wu HL,. Modulation of Dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation, and bone mass loss. Endocrinology 2008; 149: 1793-801.
32. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O'Brien CA, et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 2005; 146: 4577-83. (Pubitemid 41446595)
33. Leupin O, Kramer I, Collette NM, Loots GG, Natt F, Kneissel M, et al. Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J Bone Miner Res 2007; 22: 1957-67. (Pubitemid 351229312)
34. Silvestrini G, Ballanti P, Leopizzi M, Sebastiani M, Berni S, Di Vito M, et al. Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone. J Mol Histol 2007; 38: 261-9. (Pubitemid 47106897)
35. Van Buul-Offers SC, Smink JJ, Gresnigt R, Hamers N, Koedam J, Karperien M,. Thyroid hormone, but not parathyroid hormone, partially restores glucocorticoid-induced growth retardation. Pediatr Nephrol 2005; 20: 335-41. (Pubitemid 40309939)
36. Oxlund H, Ortoft G, Thomsen JS, Danielsen CC, Ejersted C, Andreassen TT,. The anabolic effect of PTH on bone is attenuated by simultaneous glucocorticoid treatment. Bone 2006; 39: 244-52. (Pubitemid 43851361)
37. Leclerc N, Noh T, Khokhar A, Smith E, Frenkel B,. Glucocorticoids inhibit osteocalcin transcription in osteoblasts by suppressing Egr2/Krox20-binding enhancer. Arthritis Rheum 2005; 52: 929-39. (Pubitemid 40365117)
38. Ducy P, Desbois C, Boyce B, Pinero G, Story B, Dunstan C, et al. Increased bone formation in osteocalcin-deficient mice. Nature 1996; 382: 448-52. (Pubitemid 26264860)
39. Van Lierop AH, Hamdy NA, Papapoulos SE,. Glucocorticoids are not always deleterious for bone. J Bone Miner Res 2010; 25: 2520-4.